● Recruiting

Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL

Condition: B-NHL · CART Therapy · Sponsor: Ruijin Hospital

PhasePhase 2

Planned participants144

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This study aims to explore whether adding immunotherapy bridging treatment for low-risk refractory/relapsed B-NHL can demonstrate better outcomes, in order to find the most effective treatment plan for low-risk patients.

This description comes directly from the study's public registry record.

Talk to the study team

zhao wei li, doctor Degree · +862164370045 · zwl_trial@163.com

yan zi xun, doctor degree · +862164370045 · yzx12119@rjh.com.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Ruijin

Shanghai, Shanghai Municipality, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06695013